[CAS NO. 442201-24-3]  Remogliflozinetabonate

Remogliflozin etabonate (GSK189075; 10 or 30 mg/kg; orally; twice daily for 6 weeks) significantly reduced both the FPG and GHb levels in a dosedependent manner ^[1] .
Remogliflozin etabonate (3, 10, 30 mg/kg; orally) increases urinary glucose excretion in a dose-dependent manner. Remogliflozin etabonate dose-dependently inhibits the increase in plasma glucose after glucose loading and decreases the plasma insulin in normal rats ^[1] .
Remogliflozin etabonate (1-10 mg/kg; orally) decreases the blood glucose and reduces the AUC _{0–6 h} for blood glucose in a dose-dependent manner ^[1] .
Remogliflozin etabonate (high-fat diet containing 0.01, 0.03, or 0.1% remogliflozin etabonate for 8 weeks) reduces the levels of plasma glucose, plasma insulin, and GHb in a dose-dependent manner, and it suppresses the development of hypertriglyceridemia in male GK rats (6 weeks of age) ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.